carmustine has been researched along with Burkitt Lymphoma in 12 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Burkitt Lymphoma: A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The experimental programme was safe and active in a multicentre setting, with only two episodes of grade 4 non-haematological toxicity (hepatotoxicity and mucositis), and no cases of systemic fungal infections; two patients died of toxicity (bacterial infections)." | 3.01 | A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial. ( Allione, B; Calimeri, T; Cattaneo, C; Donadoni, G; Facchetti, F; Ferrari, D; Ferreri, AJM; Foppoli, M; Fumagalli, L; Lleshi, A; Pecciarini, L; Ponzoni, M; Re, A; Rigacci, L; Rossi, G; Sassone, M; Spina, M; Verga, L, 2021) |
| "Burkitt lymphoma is an aggressive B cell malignancy accounting for 1-2% of all adult lymphomas." | 1.48 | Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. ( Baars, JW; Brouwer, R; Chamuleau, MED; de Jong, D; de Wreede, LC; Demandt, AMP; Doorduijn, JK; Hardi, L; Kersten, MJ; Kluin, PM; Nijland, M; Oosten, LEM; Siemes, C; Smeekes, OS; Stevens, WBC; Thielen, FW; Uyl-de Groot, CA; van Imhoff, GW; Veelken, H, 2018) |
| "The human Burkitt's lymphoma cell line BHM fails to show synergistic killing by alkylating agents in the presence of theophylline." | 1.27 | Theophylline does not reverse DNA replicon initiation inhibition in human cells resistant to alkylating agent-theophylline killing synergism. ( Ducore, JM; Rosenstein, BS, 1984) |
| "Fourteen patients with American Burkitt's lymphoma resistant to conventional chemotherapy were treated with high-dose combination chemotherapy and intensive supportive care." | 1.26 | Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. ( Appelbaum, FR; Deisseroth, AB; Graw, RG; Herzig, GP; Levine, AS; Magrath, IT; Pizzo, PA; Poplack, DG; Ziegler, JL, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (58.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreri, AJM | 1 |
| Cattaneo, C | 2 |
| Lleshi, A | 1 |
| Verga, L | 1 |
| Allione, B | 1 |
| Facchetti, F | 1 |
| Ponzoni, M | 1 |
| Foppoli, M | 2 |
| Ferrari, D | 1 |
| Rigacci, L | 1 |
| Pecciarini, L | 1 |
| Donadoni, G | 2 |
| Fumagalli, L | 2 |
| Sassone, M | 1 |
| Calimeri, T | 1 |
| Rossi, G | 2 |
| Spina, M | 2 |
| Re, A | 2 |
| Oosten, LEM | 1 |
| Chamuleau, MED | 1 |
| Thielen, FW | 1 |
| de Wreede, LC | 1 |
| Siemes, C | 1 |
| Doorduijn, JK | 1 |
| Smeekes, OS | 1 |
| Kersten, MJ | 1 |
| Hardi, L | 1 |
| Baars, JW | 1 |
| Demandt, AMP | 1 |
| Stevens, WBC | 1 |
| Nijland, M | 1 |
| van Imhoff, GW | 1 |
| Brouwer, R | 1 |
| Uyl-de Groot, CA | 1 |
| Kluin, PM | 1 |
| de Jong, D | 1 |
| Veelken, H | 1 |
| Ferreri, AJ | 1 |
| Bruno Ventre, M | 1 |
| Mappa, S | 1 |
| Govi, S | 1 |
| Di Nicola, M | 1 |
| Tirelli, U | 1 |
| Caligaris-Cappio, F | 1 |
| Dallegri, F | 2 |
| Patrone, F | 2 |
| Frumento, G | 2 |
| Sacchetti, C | 1 |
| Ducore, JM | 2 |
| Rosenstein, BS | 1 |
| Jost, LM | 1 |
| Jacky, E | 1 |
| Dommann-Scherrer, C | 1 |
| Honegger, HP | 1 |
| Maurer, R | 1 |
| Sauter, C | 1 |
| Stahel, RA | 1 |
| Appelbaum, FR | 1 |
| Deisseroth, AB | 1 |
| Graw, RG | 1 |
| Herzig, GP | 1 |
| Levine, AS | 1 |
| Magrath, IT | 2 |
| Pizzo, PA | 1 |
| Poplack, DG | 1 |
| Ziegler, JL | 2 |
| Suvatte, V | 1 |
| Issaragrisil, S | 1 |
| Chandanayingyong, D | 1 |
| Mahasandana, C | 1 |
| Tanphaichitr, VS | 1 |
| Jirapinyo, P | 1 |
| Wysenbeek, YS | 1 |
| Nissenkorn, I | 1 |
| Cohen, S | 1 |
| Ben-Sira, I | 1 |
| Stark, B | 1 |
| Zaizov, R | 1 |
| Schein, PS | 1 |
| O'Connell, MJ | 1 |
| Blom, J | 1 |
| Hubbard, S | 1 |
| Bergevin, P | 1 |
| Wiernik, PH | 1 |
| DeVita, VT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors[NCT00001301] | 107 participants | Observational | 1992-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for carmustine and Burkitt Lymphoma
| Article | Year |
|---|---|
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2021 |
Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1995 |
Clinical antitumor activity and toxicity of streptozotocin (NSC-85998).
Topics: Adenoma, Islet Cell; Blood Cells; Burkitt Lymphoma; Carcinoid Tumor; Carmustine; Clinical Trials as | 1974 |
9 other studies available for carmustine and Burkitt Lymphoma
| Article | Year |
|---|---|
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carmustin | 2018 |
Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carmustine; Cytarabine; Fem | 2012 |
Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms.
Topics: Antibody-Dependent Cell Cytotoxicity; Aprotinin; Blood Glucose; Burkitt Lymphoma; Carmustine; Cell L | 1984 |
Mechanisms of tumour cell destruction by PMA-activated human neutrophils.
Topics: Burkitt Lymphoma; Carmustine; Cell Line; Chlorides; Cytotoxicity, Immunologic; Humans; Hydrogen Pero | 1983 |
Theophylline does not reverse DNA replicon initiation inhibition in human cells resistant to alkylating agent-theophylline killing synergism.
Topics: Alkylating Agents; Burkitt Lymphoma; Carmustine; Cell Line; Cell Survival; Cisplatin; Cross-Linking | 1984 |
Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse.
Topics: Adolescent; Adult; Burkitt Lymphoma; Carmustine; Child; Child, Preschool; Cyclophosphamide; Cytarabi | 1978 |
Massive chemotherapy and autologous bone marrow transplantation in Burkitt's lymphoma: the first two patients successfully treated in Thailand.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Burkitt Lymphoma; Carmu | 1990 |
alpha-Difluoromethylornithine effects on nitrosourea-induced cytotoxicity and crosslinking in a methylation excision repair positive (MER+) human cell line.
Topics: Burkitt Lymphoma; Carmustine; Cell Line; Cell Survival; DNA; DNA Repair; Eflornithine; Ethylnitrosou | 1987 |
Intraocular involvement of Burkitt's lymphoma in a Bedouin child.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Burkitt Lympho | 1987 |